Teijin Ltd - Company Profile
Powered by 
All the data and insights you need on Teijin Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Teijin Ltd Strategy Report
- Understand Teijin Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
Teijin Ltd (Teijin) is a technology-driven holding company that offers solutions in the areas of information and electronics, healthcare, environment and energy and safety and protection. The company manufactures and sells aramid fiber, carbon fiber products, synthetic fiber, films, polyester films, resin products, chemical products, IT products and pharmaceutical products. Teijin offers pharmaceuticals for treating bone and joint diseases, respiratory diseases, cardiovascular and metabolic diseases, and other diseases. It also offers homecare services such as home oxygen therapy devices, sonic accelerated fracture healing systems and sleep-disordered breathing-related devices, among others. The company operates facilities in Europe, America, Asia and Japan. It sells its products in Asia, the Americas and Europe. Teijin is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
Kasumigaseki Common Gate West Tower, 3-2-1, Kasumigaseki, Chiyoda-Ku, Tokyo, 100-8585
Website
www.teijin.co.jp
Telephone
81 3 35064529
No of Employees
22,484
Industry
Chemicals
Ticker Symbol & Exchange
3401 (TYO)
Revenue (2022)
$7.5B
10%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-176.4%
(2022 vs 2021)
Market Cap*
$2.0B
Net Profit Margin (2022)
XYZ
-169.6%
(2022 vs 2021)
* As of and is in US$
Teijin Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Materials: | Content | Loqoa |
| Processed Film | Synthetic Fibers | Tetoron |
| Aramid Fibers | Resin & Plastic Processing Services | Twaron / Technora |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In February, the company collaborated with JRCCN on experiments using hydrogen fuel cell generators. |
| 2024 | Contracts/Agreements | In January, the company signed a joint research and development agreement with Garwood Medical Devices to launch Garwood’s novel infection control technology in Japan. |
| 2023 | Contracts/Agreements | In September, the company signed an agency contract with Garzanti Specialties S.p.A to sell Teijin’s highly nutritious BARLEYmaxTM super barley in Europe. |
Competitor Comparison
| Key Parameters | Teijin Ltd | Takeda Pharmaceutical Co Ltd | Mitsubishi Chemical Corp | Sumitomo Chemical Co Ltd | Celanese Corp |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | United States of America |
| City | Chiyoda-Ku | Chuo-Ku | Tokyo | Chuo-Ku | Irving |
| State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Texas |
| No. of Employees | 22,484 | 49,095 | 42,127 | 33,572 | 12,410 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Akimoto Uchikawa | Director; Chief Executive Officer; President | Executive Board | 2022 | - |
| Noboru Yamanishi | Head - Corporate Audit Department; Executive Officer; Chief Sustainability Officer; Director; Head - Engineering Division | Executive Board | 2023 | - |
| Eiji Ogawa | Director; Chief Financial Officer - Procurement and Logistics Division; Senior Executive Officer | Executive Board | 2023 | - |
| Naohiko Moriyama | Senior Executive Officer; Chief Officer - Corporate Strategy; Director | Executive Board | 2023 | - |
| Masaki Taneda | President - General Manager - Healthcare Business Management Division - Teijin Ltd; President - Teijin Pharma Ltd; General Manager - Healthcare Business Unit; President - General Manager - Business Management Division, Teijin Pharma Ltd; Executive Officer | Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward